Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for life-threatening infections. The company’s lead investigational drug, tedizolid phosphate, is a once daily, IV, and orally administered second generation oxazolidinone that completed Phase III clinical development for the treatment of acute bacterial skin and skin structure infections. It also has two preclinical programs to identify and develop antibiotics to treat infections caused by gram-negative and gram–positive bacteria; and the marine natural products preclinical program to identify and develop antibiotics for use as countermeasures for biodefense threats. Trius Therapeutics has a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and commercialize licensed products, including tedizolid phosphate, outside of Korea; a cooperative research and development agreement with Lawrence Livermore National Security LLC for researching and developing gram-negative biodefense pathogens; a research agreement with UCSD for jointly researching antibacterial agents for combating gram-negative and gram-positive biodefense pathogens; a research contract with Lawrence Livermore National Laboratory for the development of antibiotics directed against gram negative multi-drug resistant bacterial pathogens; and a collaboration and license agreement with Bayer to develop and commercialize tedizolid phosphate in the Bayer licensed territory. The company was formerly known as Rx3 Pharmaceuticals, Inc. and changed its name to Trius Therapeutics, Inc. in February 2007. Trius Therapeutics, Inc. was incorporated in 2004 and is headquartered in San Diego, California.